JNTX 104
Alternative Names: JNTX-104Latest Information Update: 28 Jul 2024
At a glance
- Originator City of Hope National Medical Center; January Therapeutics
- Class Albumins; Alcohols; Amines; Antineoplastics; Chlorinated hydrocarbons; Chlorine compounds; Purines; Ribonucleosides; Small molecules
- Mechanism of Action Antimetabolites; RNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for research development in Cancer in USA
- 01 Jul 2021 January Therapeutics has patents pending for nanoparticle compositions comprising organophosphate compounds and pharmaceutically acceptable carrier such as albumin in Japan, China, European Union, Australia, USA and Canada
- 31 Aug 2020 January Therapeutics files for patent protection for nanoparticle compositions comprising organophosphate compounds and pharmaceutically acceptable carrier such as albumin in South Korea, Singapore and in Israel